Innoviva, Inc. (NASDAQ: INVA), based in California, USA, is a forward-looking biopharmaceutical company committed to bringing transformative, innovative medical solutions to patients worldwide. The company is deeply embedded in the field of respiratory medication, primarily focusing on the successful commercialization of unique, patented therapies for chronic obstructive pulmonary disease (COPD) and asthma.
Initially founded in 1996 as Theravance, Innoviva was rebranded in 2016 to better reflect its strategic vision: breathing new life into pharmaceutical innovation. The company has a long track record of partnering with some of the leading global pharmaceutical and biotech companies, including GlaxoSmithKline (GSK), with whom Innoviva co-developed TRELEGY ELLIPTA, a once-daily, single inhaler triple therapy for COPD.
Innoviva's business model is unique. Rather than manufacturing and distributing therapies itself, Innoviva banks on its expertise in identifying, developing, and commercializing unique therapies sourced from global partners. The company then earns revenue through royalty payments received from these pharmaceutical partnerships.
Asides from TRELEGY ELLIPTA, its partnership with GSK has also given birth to other novel medicines that include RELVAR/BREO ELLIPTA, a once-daily combination of drugs to treat COPD and asthma, and ANORO ELLIPTA, another once-daily treatment for patients suffering from COPD.
Through the smart execution of its strategy, Innoviva continues to realize the value of its tremendous respiratory portfolio. The company has an impressive track record of transforming novel ideas into commercially successful therapies, reflecting its competitive edge in navigating the complex process of drug development through to commercialization.
Innoviva’s successful track record is further enhanced by its experienced management team comprised of accomplished leaders in the healthcare and pharmaceutical industries. Their combined wealth of knowledge and extensive industry relationships continuously drive the company's leadership in the development of novel treatments ensuring long-term value for its stakeholders.
Innoviva's business model and strategic alliances position it well to remain a significant contributor in the sphere of respiratory medication which contributes positively towards improving the quality of life for millions of patients globally.
Through decades of dynamic operations, Innoviva has successfully positioned itself as a global powerhouse in the commercialization of unique, cutting-edge respiratory solutions. Its commitment to continuous innovation and deep industry connections lay a solid foundation for potential growth and global impact in the years to come.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
_07_03_2026_03_50_21_133108.jpg)
Innoviva CEO and Director Pavel Raifeld executed a tax-related share withholding transaction on August 20, 2026. This involved the disposition of 1,130 shares of common stock at $21 per share to cover income tax obligations from vested employee equity awards. Following this transaction, Raifeld directly beneficially owns 284,799 shares of Innoviva, Inc. common stock.
Cantor Fitzgerald has reiterated an overweight rating for Innoviva Technology, Inc. with a $34 price target, noting the company's successful evolution into a diversified biopharma with strong commercial growth and strategic healthcare assets. Innoviva shows profitable growth with a 50%+ CAGR, an undervalued stock based on a low P/E ratio and InvestingPro analysis, and a strong balance sheet with more cash than debt. Recent developments include exceeding revenue forecasts, launching a new subsidiary for drug delivery, and securing international distribution agreements.
NewEdge Wealth LLC has acquired a new stake in Innoviva, Inc. (NASDAQ:INVA) during the second quarter, purchasing 99,367 shares valued at approximately $2.26 million. This move makes NewEdge Wealth LLC own about 0.13% of the biotechnology company, while institutional investors collectively hold 99.12% of Innoviva. Analyst sentiment is mixed, with a consensus "Hold" rating and an average price target of $34.75, despite the company's shares opening at $21.00 with a market capitalization of $1.52 billion.
Innoviva, Inc. (NASDAQ:INVA) has received an average rating of "Hold" from brokerage firms, with six ratings contributing to this consensus. The company's stock opened at $21.00, has a market cap of $1.52 billion, and a P/E ratio of 5.12. Several institutional investors have recently adjusted their holdings in Innoviva, and the company focuses on acquiring and monetizing royalty and license interests in biopharmaceutical products, particularly inhaled respiratory therapies.
Chase Investment Counsel Corp has acquired 70,000 shares of Innoviva, Inc. (NASDAQ:INVA) for approximately $1.59 million, representing a new stake of about 0.09% in the company. Institutional ownership in Innoviva remains high at 99.12%, with firms like Vanguard Group and Arrowstreet Capital also increasing their positions. Innoviva has a "Hold" consensus rating from analysts with an average price target of $34.75, despite mixed recent recommendations and a current trading price of around $21.19.
Innoviva (INVA) reported mixed Q2 2026 results with increased revenue but a net loss, contrasting with positive six-month figures. The company also completed a share buyback, signaling a focus on capital returns despite short-term earnings volatility. Investors are encouraged to consider long-term profitability and the impact of the buyback against recent index removals.
Innoviva (INVA) recently reported a Q2 2026 net loss of US$83.42 million despite increased revenue, alongside completing a US$66.40 million share buyback. While the quarterly loss introduces volatility, the company's six-month figures show overall revenue and net income growth, suggesting a complex investment narrative involving historical profitability, low earnings multiples, and capital returns. The article suggests investors consider these factors along with differing fair value estimates and potential risks related to earnings quality.
This article analyzes Innoviva Inc. (NASDAQ: INVA) using AI models, identifying divergent sentiment across time horizons and suggesting choppy market conditions. It provides specific institutional trading strategies, including position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis for support and resistance levels. The report highlights elevated downside risk due to the absence of long-term support signals.
Innoviva, Inc. reported a Q2 2026 net loss of US$83.42 million despite increased revenue, leading to a loss per share of US$1.14 from continuing operations. This quarterly loss contrasts with strong first-half net income, creating a volatile earnings picture. The company's recent US$66.40 million share buyback program, which retired 4.12% of shares, aims to return capital to shareholders amidst these fluctuating results and shifting market sentiment.